Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Paragraph: The number of EU nurses coming to the UK has fallen by 90% since the Brexit vote. The number of nurses and midwives from the EEA joining the Nursing and Midwifery Council’s register fell by 91% from 2015/16 to 2017/18. The number of EU nationals leaving the NHS jumped by 14% in 2017. EU nationals have fallen as a percentage of those joining the NHS. EU nationals made up 8% of new staff (whose nationality was known) joining the NHS in England in the year to June 2018. That compares to 11% in the year to June 2016. It’s possible that the number in June 2016 was unusually high. Claim 1 of 4 Claim: EU nationals have fallen as a percentage of those joining the NHS.
EU nationals made up 8% of new staff (whose nationality was known) joining the NHS in England in the year to June 2018. That compares to 11% in the year to June 2016. It’s possible that the number in June 2016 was unusually high.

Paragraph: Urinary incontinence or loss of bladder control is by far  the most common problem, and childbirth, which can weaken  pelvic floor muscles, is the most frequent cause. “What stands out is such a large number of women had  symptoms of a moderate-to-severe pelvic floor disorder,” said  Dr. Ingrid Nygaard of the University of Utah, whose study  appears in Journal of the American Medical Association. “We know many women leak urine once in a blue moon if they  are doing strenuous exercise. That such a large number leaks on  a regular basis was surprising to see,” she said by telephone. Nygaard’s team studied 1,961 nonpregnant women aged 20 and  older who were part of a national health survey in 2005-2006. They were examined for symptoms of urinary and fecal  incontinence and pelvic organ prolapse, in which an organ such  as the bladder drops and pushes against the walls of the  vagina. Overall, 23.7 percent of women reported symptoms of at  least one pelvic floor disorder. Of these, 15.7 percent had  urinary incontinence, 9 percent had fecal incontinence and 2.9  percent had pelvic organ prolapse, in which women reported  seeing or feeling a vaginal bulge. Age plays a major role, with just 10 percent of women 20 to  39 reporting at least one disorder, compared with about a  quarter of women 40 to 59, 37 percent of women 60 to 79, and  nearly half of women 80 and older. Women were considered to have urinary incontinence if they  had at least weekly leakage, or monthly leakage of volumes of  more than just a few drops. If women with occasional leakage were included, the numbers  might be much higher, the researchers said. “The study results underscore the need to identify the  causes of pelvic floor disorders and the means to prevent and  treat them,” Dr. Duane Alexander, director of the National  Institute of Child Health and Human Development, said in a  statement. Treatments for urinary stress incontinence — the kind  linked with laughing, coughing, sneezing or exercise — range  from exercises to surgical options. Urge incontinence or overactive bladder can be treated by  lifestyle changes and a number of drugs, including tolterodine  or Detrol made by Pfizer Inc; Vesicare or solifenacin made by  GlaxoSmithKline and Astellas Pharma Inc; and Enablex or  darifenacin by Novartis AG. Claim: Pelvic disorders common among women: study.
Nearly one quarter of all U.S. women  have some sort of pelvic floor disorder such as urinary or  fecal incontinence, and more cases are likely as the population  ages, researchers said on Tuesday.

Paragraph: The results marked the third successful Phase III test of the drug evolocumab reported by Amgen in recent months - this one in a patient population among the most in need of alternative therapies. An estimated five to 20 percent of heart patients are intolerant of statin medications for lowering cholesterol due to side effects such as muscle weakness or fatigue, Amgen said. Evolocumab belongs to a class of medicine called PCSK9 inhibitors that work by blocking a protein that reduces the liver’s ability to remove LDL cholesterol from the blood. Based on dramatic LDL lowering demonstrated by Amgen and other companies in earlier studies, PCSK9 inhibitors could be the most important new heart drugs to come along in several years with multibillion-dollar sales potential. The injected medicines are likely to be used in high risk heart patients unable to lower their LDL levels sufficiently with high doses of widely used statin drugs, such as Pfizer’s Lipitor, and in those unable to take statins. Many patients remain at high risk of heart attack and stroke “despite the use of all available therapies,” Amgen research and development chief Sean Harper said in a telephone interview. “The ability to treat those individuals with a completely distinct mechanism and see this very large effect size of dropping LDL cholesterol by roughly 50 percent, that’s a pretty big deal for those patients,” Harper said. The company expects during the current quarter to have results of its final two Phase III studies - one in patients already taking high doses of statins and one in patients genetically predisposed to dangerously high cholesterol levels. Amgen will provide details of its latest 307-patient Phase III study, called GAUSS-2, which compared evolocumab to Merck & Co’s Zetia (ezetimibe), at an upcoming medical meeting. However, the world’s largest biotech company said the percentage of cholesterol lowering was consistent with those observed in a similar, smaller Phase II trial. In that study, evolocumab led to 51 percent reduction in LDL levels and 63 percent when combined with Zetia versus a 15 percent reduction seen with Zetia alone. “It’s very unusual to have a therapeutic that addresses one of the underlying factors that drive the greatest mortality risk that exists in Western countries, and increasingly in developing countries - cardiovascular disease driven by atherosclerosis,” Harper said. The company anticipates that some of its global filings seeking approval of the drug will occur this year. “We don’t come across therapeutics like this very often in this industry,” Harper said. “It is very exciting, and as we get each data set our confidence slowly builds that we have the efficacy and the safety profile that will make this an important medicine.”  Regeneron Pharmaceuticals Inc, in partnership with Sanofi, is also in Phase III testing of a rival drug. Pfizer is developing its own PCSK9 inhibitor. Amgen shares were down about 0.6 percent at $123.55 on Nasdaq, roughly in line with declines in the broader market. Claim: Amgen cholesterol drug meets goal of 3rd late stage trial.

A cholesterol fighter developed by Amgen Inc from a highly promising new class of medicines significantly lowered levels of “bad” LDL cholesterol in a late stage trial in patients unable to tolerate statin drugs, the company said on Thursday.